Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Scientists Halt FEM-PrEP Study in Africa

April 18, 2011

Scientists Halt FEM-PrEP Study in Africa

On Monday scientists terminated a study in Africa designed to figure out whether a daily oral dose of the antiretroviral Truvada could prevent women from becoming infected with HIV.

According to FHI, the global health organization conducting the study, early results showed no evidence that the pill was effective.

The study's premature termination disappointed AIDS activists who had high hopes for its results -- but excited others who oppose the FDA's potential approval of Truvada for this purpose.

In cased you missed it, here's the report from the New York Times.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Housing Works. It is a part of the publication Housing Works AIDS Issues Update. Visit Housing Works' website to find out more about their activities, publications and services.
 
See Also
PrEP Ineffective for Women? Study on Truvada for HIV Prevention Is Unexpectedly Cut Short
Results of FEM-PrEP Clinical Trial Examining Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among Heterosexual Women
Global Campaign for Microbicides Statement on the Discontinuation of the FEM-PrEP Trial
The FEM-PrEP HIV Prevention Study and Its Implications for NIAID Research
More News and Research on HIV Medications for HIV Prevention

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement